A multi-centre, open label, single arm, Ph IV, interventional study to evaluate the efficacy of Erlotinib following 4 cycles of platinum-based chemotherapy in pts with locally advanced or metastatic NSCLC who have not experienced disease progression or unacceptable toxicity during chemotherapy.
Latest Information Update: 05 Nov 2010
Price :
$35 *
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 05 Nov 2010 New trial record